Recombinant Biotinylated Human G-CSF R / CD114 Protein, Avi Tag (Avitag™), His tag, 25µg

Background
Granulocyte Colony Stimulating Factor Receptor (G-CSFR) is also known as Cluster of Differentiation 114 (CD114), CSF3R and GCSF, is a cell-surface receptor for the granulocyte colony-stimulating factor (G-CSF), a cytokine that plays a critical role in the regulation of the activation, proliferation, differentiation, and survival of the neutrophilic granulocyte lineage. G-CSFR belongs to a family of cytokine receptors known as the hematopoietin receptor family. This type I  membrane protein has a composite structure consisting of an immunoglobulin(Ig)-like domain, a cytokine receptor-homologous (CRH) domain and three fibronectin type I II (FNIII) domains in the extracellular region. G-CSFR is present mainly on precursor cells in the bone marrow, and, in response to stimulation by G-CSF, initiates cell proliferation and differentiation into mature neutrophilic granulocytes and macrophages. G-CSFR mediates the specific effect of GCSF through activating a variety of intracellular signaling cascades, including the Jak/Stat, PI3/Akt, Ras-Raf-MAP kinase, and Src family kinase pathways, and thus functions in defense against infection, inflammation and repair, and in the maintenance of steady state hematopoiesis. Mutations in this gene are a cause of Kostmann syndrome, also known as severe congenital neutropenia. Mutations in the intracellular part of this receptor are also associated with certain types of leukemia.

Source
Recombinant Biotinylated Human G-CSF R, Avitag,His Tag (GCR-H82E4) is expressed from human 293 cells (HEK293). It contains AA Glu 25 - Pro 621 (Accession # NP_000751).
Predicted N-terminus: Glu 25

Molecular Characterization
This protein carries an Avi tag (Avitag™) at the C-terminus, followed by a polyhistidine tag.
The protein has a calculated MW of 69.2 kDa. The protein migrates as 85-100 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Biotinylation
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Biotin:Protein Ratio
Passed as determined by the HABA assay / binding ELISA.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20^°C to -70^°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.
 
Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Cardiac and inflammatory biomarker differences in adverse cardiac events after chimeric antigen receptor T-Cell therapy: an exploratory study
Lee, Chandrasekhar, Jain et al
Cardiooncology (2023) 9 (1), 18
(2) "Inhibition of LXR controls the polarization of human inflammatory macrophages through upregulation of MAFB
de la Aleja, Herrero, Torres-Torresano et al
Cell Mol Life Sci (2023) 80 (4), 96
(3) "Vertebral Compression Fractures in Very Early Onset Inflammatory Bowel Disease
Collen, Snapper, Gordon
JPGN Rep (2023) 4 (1), e283
Showing 1-3 of 2189 papers.

Limited Use License
The Biotin AviTag technology is covered by U.S. Pat. No: 5,874,239 and includes any and all materials, methods, kits and related derivatives claimed by this patent. The purchase of the Acrosbiosystems’s Avitag™ proteins confers to the purchaser the limited right to use the Avitag™ technology for non-commercial, or research use, or for purposes of evaluating the Avitag™ technology.
Commercial use of the Avitag™ technology to manufacture a commercial product, or use of the Avitag™ technology to facilitate or advance research which will be applied to the development of a commercial product requires a license from Avidity, LLC. Examples of Commercial use include, but are not limited to biosensors, diagnostics, therapeutic applications, proximity assays, and drug screening assays.